Belgium’s UCB inks global biotech deal with China’s Antengene

EURACTIV - Belgian biopharmaceutical company UCB has signed a global licensing deal with China's Antengene for an experimental immunology therapy, highlighting how Western drugmakers are increasingly sourcing early-stage innovation from China's rapidly expanding biotech sector. Read more

[Getty Images: Edwin Tan]